Propagermanium clinical trials
Also written DMX-200 and repagermanium.
How each study uses propagermanium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the propagermanium studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2018 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Dimerix Bioscience Pty Ltd (3) · University of Sydney (1) · Arizona Oncology Services (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses propagermanium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARBRecruitingPhase 3Dimerix Bioscience Pty LtdNCT05183646Written as DMX-200
- Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19TerminatedPhase 2University of SydneyNCT05122182Written as Repagermanium
- Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving IrbesartanCompletedPhase 2Dimerix Bioscience Pty LtdNCT03649152Written as Propagermanium
- Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving IrbesartanCompletedPhase 2Dimerix Bioscience Pty LtdNCT03627715Written as Propagermanium
- Use of Organic Germanium or Placebo for the Prevention of Radiation Induced FatigueStatus unknownPhase 2Arizona Oncology ServicesNCT00651417Written as Organic Germanium
Codes
What other systems call propagermanium · ClinicalTrials.gg INT003545
- MeSH (NLM) C066750propagermaniumConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1Q2P9TO9Q7PROPAGERMANIUMConfirmed FDA, NLM
- RxNorm 158660One source FDA
- NCI Thesaurus C171759PropagermaniumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C066750 | propagermanium | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1Q2P9TO9Q7 | PROPAGERMANIUM | Confirmed FDA, NLM |
| RxNorm | 158660 | — | One source FDA |
| NCI Thesaurus | C171759 | Propagermanium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.